N@N

Matthew Harrison Maintained (ALNY) at Hold with Decreased Target to $210 on, Oct 28th, 2022

Matthew Harrison of Morgan Stanley, Maintained "Alnylam Pharmaceuticals, Inc." (ALNY) at Hold with Decreased Target from $220 to $210 on, Oct 28th, 2022.

Matthew has made no other calls on ALNY in the last 4 months.

There are 9 other peers that have a rating on ALNY. Out of the 9 peers that are also analyzing ALNY, 4 agree with Matthew's Rating of Hold. Following are those relevant analyst calls for the last 4 months

---

• Jessica Fye of "JP Morgan" Maintained at Hold with Decreased Target to $200 on, Monday, October 24th, 2022
• Gary Nachman of "BMO Capital" Maintained at Hold with Increased Target to $200 on, Friday, September 9th, 2022
• David Lebowitz of "Morgan Stanley" Maintained at Hold with Decreased Target to $164 on, Friday, July 15th, 2022
• Olivia Brayer of "Cantor Fitzgerald" Initiated at Hold and Held Target at $175 on, Wednesday, July 13th, 2022

These are the ratings of the 5 analyists that currently disagree with Matthew

---

• Maury Raycroft of "Jefferies" Maintained at Strong Buy with Increased Target to $232 on, Monday, October 3rd, 2022
• Luca Issi of "RBC Capital" Maintained at Buy with Increased Target to $250 on, Tuesday, September 20th, 2022
• Leland Gershell of "Oppenheimer" Maintained at Buy with Increased Target to $256 on, Friday, September 9th, 2022
• Joseph Stringer of "Needham" Maintained at Strong Buy with Increased Target to $240 on, Thursday, August 4th, 2022
• Keay Nakae of "Chardan Capital" Maintained at Strong Buy with Increased Target to $250 on, Thursday, August 4th, 2022

Contributing Sources

---